Guy M. Gammon
Nessuna posizione attualmente
Profilo
Guy M.
Gammon is Chief Medical Officer of Receptor Biologix, Inc. Prior to joining Receptor Biologix, he was Vice President of CancerVax Corp.
Previously, Dr. Gammon was Senior Director of Clinical Trials for the John Wayne Cancer Institute and Vice President of Clinical Development for Micromet, Inc. Before joining John Wayne Cancer Institute, he was Program Head of Immunology Drug Discovery for Xenova Plc.
Dr. Gammon was an Assistant Research Immunologist at University of California, Los Angles.
He was a Member of the Royal College of Physicians in 1982.
Dr. Gammon has over 20 years of experience in biomedical research and 10 years experience in the biotechnology industry.
He received an MD from the University College Hospital Medical School in London in 1979.
Precedenti posizioni note di Guy M. Gammon
| Società | Posizione | Fine |
|---|---|---|
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Corporate Officer/Principal | 14/07/2006 |
| CancerVax Corp. | Corporate Officer/Principal | 09/05/2006 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
| University of California, Davis | Corporate Officer/Principal | - |
Xenova Group Plc
 Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Corporate Officer/Principal | - |
Formazione di Guy M. Gammon
| University College London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 5 |
|---|---|
| CancerVax Corp. | Commercial Services |
Receptor BioLogix, Inc.
 Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Prospect Therapeutics, Inc.
 Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Health Technology |
Xenova Group Plc
Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Commercial Services |
- Borsa valori
- Insiders
- Guy M. Gammon
